Sustained complete remission following a combination of very low intensity chemotherapy with rituximab in an elderly patient with Burkitt's lymphoma.
Cohen
Yossi
Y
Department of Hematology, Hadassah University Hospital, Jerusalem, Israel 91120.
Amir
Gail
G
Rachmilewitz
Eliezer A
EA
Polliack
Aaron
A
D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000532:radiotherapy / Q000556:secondary / Q000601:surgery; D002051:Burkitt Lymphoma / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000532:radiotherapy / Q000601:surgery; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007167:Immunotherapy; D015412:Mastectomy, Segmental; D009378:Neoplasms, Multiple Primary; D009918:Orbital Neoplasms / Q000188:drug therapy / Q000628:therapy*; D011241:Prednisone / Q000008:administration & dosage; D018714:Radiotherapy, Adjuvant; D012074:Remission Induction; D000069283:Rituximab; D016879:Salvage Therapy; D014750:Vincristine / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone